Literature DB >> 21976767

Dried culture spots for Xpert MTB/RIF external quality assessment: results of a phase 1 pilot study in South Africa.

L E Scott1, N Gous, B E Cunningham, B D Kana, O Perovic, L Erasmus, G J Coetzee, H Koornhof, W Stevens.   

Abstract

Implementation of Xpert MTB/RIF requires quality assessment. A pilot program using dried culture spots (DCSs) of inactivated Mycobacterium tuberculosis is described. Of 274 DCS results received, 2.19% generated errors; the remainder yielded 100% correct Mycobacterium tuberculosis detection. The probe A cycle threshold (C(T)) variability of three DCS batches was ≤ 3.47. The study of longer-term DCS stability is ongoing.

Entities:  

Mesh：

Year:  2011        PMID： 21976767      PMCID： PMC3232964          DOI： 10.1128/JCM.05167-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  24 in total

1.  Comparison of flow cytometric and Alamar Blue tests with the proportional method for testing susceptibility of Mycobacterium tuberculosis to rifampin and isoniazid.

Authors:  Roberto S Reis; Ivan Neves; Sergio L S Lourenço; Leila S Fonseca; Maria Cristina S Lourenço
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

2.  Rapid and simple quantification of bacterial cells by using a microfluidic device.

Authors:  Chieko Sakamoto; Nobuyasu Yamaguchi; Masao Nasu
Journal:  Appl Environ Microbiol       Date:  2005-02       Impact factor: 4.792

3.  African regional external quality assessment for CD4 T-cell enumeration: development, outcomes, and performance of laboratories.

Authors:  Deborah K Glencross; Hazel M Aggett; Wendy S Stevens; Frank Mandy
Journal:  Cytometry B Clin Cytom       Date:  2008       Impact factor: 3.058

4.  Evaluation of the GenoCard as a tool for transport and storage of samples for tuberculosis molecular drug susceptibility testing.

Authors:  Paolo Miotto; Federica Piana; Giovanni Battista Migliori; Daniela Maria Cirillo
Journal:  New Microbiol       Date:  2008-01       Impact factor: 2.479

5.  Safe susceptibility testing of Mycobacterium tuberculosis by flow cytometry with the fluorescent nucleic acid stain SYTO 16.

Authors:  C Pina-Vaz; S Costa-de-Oliveira; A G Rodrigues
Journal:  J Med Microbiol       Date:  2005-01       Impact factor: 2.472

6.  Method for efficient storage and transportation of sputum specimens for molecular testing of tuberculosis.

Authors:  H Guio; H Okayama; Y Ashino; H Saitoh; P Xiao; M Miki; N Yoshihara; S Nakanowatari; T Hattori
Journal:  Int J Tuberc Lung Dis       Date:  2006-08       Impact factor: 2.373

7.  Rapid susceptibility testing of Mycobacterium tuberculosis (H37Ra) by flow cytometry.

Authors:  M A Norden; T A Kurzynski; S E Bownds; S M Callister; R F Schell
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

8.  A flow cytometric technique for quantification and differentiation of bacteria in bulk tank milk.

Authors:  C Holm; T Mathiasen; L Jespersen
Journal:  J Appl Microbiol       Date:  2004       Impact factor: 3.772

9.  Viability testing of material derived from Mycobacterium tuberculosis prior to removal from a containment level-III laboratory as part of a Laboratory Risk Assessment Program.

Authors:  Kym S Blackwood; Tamara V Burdz; Christine Y Turenne; Meenu K Sharma; Amin M Kabani; Joyce N Wolfe
Journal:  BMC Infect Dis       Date:  2005-01-24       Impact factor: 3.090

10.  The resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro.

Authors:  Bavesh D Kana; Bhavna G Gordhan; Katrina J Downing; Nackmoon Sung; Galina Vostroktunova; Edith E Machowski; Liana Tsenova; Michael Young; Arseny Kaprelyants; Gilla Kaplan; Valerie Mizrahi
Journal:  Mol Microbiol       Date:  2008-02       Impact factor: 3.501
View more
  19 in total

1.  Performance monitoring of mycobacterium tuberculosis dried culture spots for use with the GeneXpert system within a national program in South Africa.

Authors:  N Gous; B Cunningham; B Kana; W Stevens; L E Scott
Journal:  J Clin Microbiol       Date:  2013-09-25       Impact factor: 5.948

2.  A pilot evaluation of external quality assessment of GenoType MTBDRplus versions 1 and 2 using dried culture spot material.

Authors:  N Gous; L E Isherwood; A David; W Stevens; L E Scott
Journal:  J Clin Microbiol       Date:  2015-01-21       Impact factor: 5.948

Review 3.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

4.  Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting.

Authors:  Lesley Scott; Anura David; Lyndel Govender; Jan Furrer; Modiehi Rakgokong; Ziyaad Waja; Neil Martinson; Gabriel Eisenberg; Elizabeth Marlowe; Wendy Stevens
Journal:  J Mol Diagn       Date:  2020-08-01       Impact factor: 5.568

Review 5.  Evaluation of the Cepheid Xpert MTB/RIF assay.

Authors:  Thomas M Shinnick; Angela M Starks; Heather L Alexander; Kenneth G Castro
Journal:  Expert Rev Mol Diagn       Date:  2014-11-06       Impact factor: 5.225

6.  Genetic Mimetics of Mycobacterium tuberculosis and Methicillin-Resistant Staphylococcus aureus as Verification Standards for Molecular Diagnostics.

Authors:  Edith Erika Machowski; Bavesh Davandra Kana
Journal:  J Clin Microbiol       Date:  2017-09-20       Impact factor: 5.948

Review 7.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Authors:  Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

8.  Multicenter feasibility study to assess external quality assessment panels for Xpert MTB/RIF assay in South Africa.

Authors:  Lesley Scott; Heidi Albert; Chris Gilpin; Heather Alexander; Kyle DeGruy; Wendy Stevens
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

9.  Using Xpert MTB/RIF.

Authors:  Mark P Nicol; Andrew Whitelaw; Stevens Wendy
Journal:  Curr Respir Med Rev       Date:  2013-06

10.  Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions.

Authors:  Wendy Stevens; Natasha Gous; Nathan Ford; Lesley E Scott
Journal:  BMC Med       Date:  2014-09-08       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.